Detalles de la búsqueda
1.
Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
Breast Cancer Res
; 22(1): 14, 2020 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-32005287
2.
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
Breast Cancer Res
; 21(1): 135, 2019 12 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31801615
3.
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Breast Cancer Res
; 20(1): 44, 2018 06 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29880014
4.
Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.
Br J Cancer
; 119(3): 313-322, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29991699
5.
Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Breast Cancer Res
; 18(1): 58, 2016 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27246191
6.
Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.
Breast Cancer Res
; 16(5): 447, 2014 Oct 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-25358600
7.
ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1.
PLoS Genet
; 7(4): e1001382, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21552322
8.
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.
Cancer Res
; 84(1): 17-25, 2024 01 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37801608
9.
Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
Breast Cancer Res
; 14(3): R78, 2012 May 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-22608253
10.
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
Breast Cancer Res
; 14(5): R132, 2012 Oct 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-23075476
11.
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.
NPJ Breast Cancer
; 8(1): 125, 2022 Nov 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36446866
12.
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
Cancer Res
; 81(4): 847-859, 2021 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33509944
13.
ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942.
Oncogene
; 39(3): 651-663, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31530935
14.
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
Oncogene
; 39(25): 4781-4797, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32307447
15.
Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients.
J Mol Diagn
; 22(1): 111-121, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31669227
16.
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance.
Nat Commun
; 11(1): 4053, 2020 08 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32792481
17.
The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
Clin Cancer Res
; 14(9): 2656-63, 2008 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18451229
18.
The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.
Cell Rep
; 29(4): 889-903.e10, 2019 10 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-31644911
19.
ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.
Endocr Relat Cancer
; 15(4): 985-1002, 2008 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-18824559
20.
The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.
Mol Cancer Ther
; 6(9): 2458-67, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17876043